Embolizing sclerosing hydrogel
A sclerosing embolizing hydrogel comprising from about 0.1% by weight to about 4.0% by weight of chitosan; from about 0.01M to about 1M of hydrochloric acid; from 0% by volume to about 40% by volume of iopamidol; from 0.5% by weight to about 25% by weight of β-glycerophosphate disodium salt; and from about 0.05% by weight to about 4% by weight of sodium tetradecyl sulphate. Also a kit for synthesizing the hydrogel and a method using the hydrogel to treat a vascular defect in a subject.
1. A kit for synthesizing a sclerosing embolizing hydrogel, said kit comprising: a first container containing chitosan in an acid solution; and a second container containing β-glycerophosphate disodium salt and sodium tetradecyl sulphate.
2. The kit of claim 1 , wherein the first container also contains an imaging contrast agent.
3. The kit of claim 1 , further comprising a mixer.
4. The kit of claim 1 , wherein the second container contains an aqueous solution in which the β-glycerophosphate disodium salt and the sodium tetradecyl sulphate are dissolved.
5. The kit of claim 2 , wherein said imaging contrast agent is selected from the group consisting of: Hypaque Meglumine, Reno, Conray, Renograffin, Hypaque Sodium, Hexabrix, Oxilan, iohexol, iopamidol, iopromide, ioversol, iodixanol, iothalamate and ioxaglate.
6. The kit of claim 5 , wherein the imaging contrast agent is iopamidol.
7. The kit of claim 5 , wherein the imaging contrast agent is a radiopaque substance.
8. The kit of claim 1 , wherein the acid is selected from the group consisting of: acetic acid, ascorbic acid, salicylic acid, phosphoric acid, hydrochloric acid, propionic acid, formic acid, lactic acid and mixtures thereof.
9. The kit of claim 8 , wherein the acid is hydrochloric acid.